We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite the disappointing results, BMS still sees strong potential for the combination treatment, noting that it significantly improved survival in six phase 3 trials for five other cancers. Read More
Pfizer and BioNTech announced Thursday that their COVID-19 vaccine is effective against the Delta variant after two doses and that a third dose will boost the protection even more. Read More
CureVac’s messenger-RNA (mRNA)-based COVID-19 vaccine, CVnCoV, was just 48 percent effective in a final analysis from a late-stage trial ― one percentage point higher than reported in an earlier phase 3 analysis and still below the FDA’s 50 percent efficacy threshold required for Emergency Use Authorization. Read More
Sanofi has already partnered with Translate Bio on one mRNA vaccine candidate that uses the same technology as the highly successful Pfizer/BioNTech and Moderna vaccines. Read More
The latest findings offer some assurance of efficacy of a booster should a third shot of the adenovirus-based vaccine be needed to protect against new variant strains. Read More
Sanofi said it plans to spend more than $475 million annually to develop messenger-RNA (mRNA) vaccines for use against a variety of infectious diseases — and expects to have at least six vaccine candidates within four years. Read More
Yescarta, Gilead Sciences’ CAR-T cell therapy for large B-cell lymphoma, is performing well in its phase 3 trial, news that came soon after Bristol Myers Squibb said its rival CAR-T cell therapy was performing favorably in its phase 3 trial. Read More